At the virtual Great Debates & Updates in Hematologic Malignancies, Dr Mikhael presented emerging therapies in multiple myeloma (MM).
At the virtual Great Debates & Updates in Hematologic Malignancies, Jonathon Cohen, MD, presented standard treatment regiments and novel agents for the treatment of MCL.
The FDA has approved lisocabtagene maraleucel, a new CAR-T therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma after at least 2 lines of systemic therapy.
The FDA granted accelerated approval to umbralisib for the treatment of adults with relapsed/refractory FL or MZL.
Study findings showed that vedolizumab 300 mg was tolerable and led to low incidence of overall and lower-intestinal aGVHD in patients who undergo allo-HSCT.
True or false: The FDA approved brentuximab vedotin injection to include peripheral T cell lymphomas in newly-diagnosed Hodgkin lymphoma.
The FDA has approved daratumumab plus hyaluronidase combined with bortezomib, cyclophosphamide, and dexamethasone (VCd) for patients with newly-diagnosed AL amyloidosis.
In a study of adults transplanted for high-risk AML or MDS, an intensified RIC regimen did not improve outcomes, regardless of pretransplant MRD status.
In a phase 3 study of older patients with AML in remission after chemo, maintenance therapy with CC-486 was tied to significantly longer survival than placebo.